An observational study in Assisted Reproductive Technology and Infertility, sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya. Status unknown. Open to participants aged 16 Years to 66 Years. Per ClinicalTrials.gov, last updated 2022-06-03.
Sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya · Observational
Human Assisted Reproductive Technology (ART) has become a very effective and nearly irreplaceable clinical treatment for infertility, helping millions of women achieve fertility. However, ART may still have potential health risks to mothers and offspring. To better research and monitor the efficacy and safety of ART, the investigators established CXARDR based on the real medical data in Reproductive and Genetic Hospital of CITIC-Xiangya, which is the world's largest ART single treatment center. CXARDR covers the ART full-cycle treatment records since the hospital perfected its electronic medical record system in 2016, as well as biological samples from the CITIC-Xiangya Genetic Resource Bank. From the preoperative investigation of ART to the 1-year follow-up of ART offspring, CXARDR provides the details of the whole process of treatment and the follow-up outcomes of ART patients, making up for the gap in the data of reproductive and obstetric institutions. The huge biological samples with clinical information also provide more possibilities for in-depth basic researches in the field of reproduction and genetics.
During the past five years (January 2016 to November 2020), the CXARDR has accumulated data concerning more than 223,000 ART treatment cycles from 120,000 infertile couples. The CXARDR also links more than 180,000 blood samples, 65,000 follicular fluid samples, 80,000 semen samples, and 31,000 granulosa cell samples from 75,000 couples. The data volume is substantial with over 800 variables being documented, and most variables are designed as structured fields. The whole process of data access, data extraction, data processing and data analysis was conducted through a dedicated server inside the CITIC-Xiangya Data Center. All investigators cannot access sensitive information, are required to sign data confidentiality agreement, and need to be approved by the CITIC-Xiangya Ethics Committee.
2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.
This study's enrollment of 119,590 is above the median of 200 across 592 observational studies indexed under Infertility.
Browse Infertility studies →Reproductive & Genetic Hospital of CITIC-Xiangya is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Infertile couples who received ART treatment in our hospital (CITIC-Xiangya).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infertile couples who came to the hospital for ART treatment
Other: Different baseline characteristics and clinical management
Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
Cleavage rate
The proportion of zygotes that cleave to become embryos on Day 2 (44 ± 1 h post-insemination) .
Time frame: Up to 3 days after insemination
Implantation rate
The number of gestational sacs divided by the total number of embryos transferred, irrespective of whether a pregnancy was established.
Time frame: Up to 30 days after transplantation
Clinical pregnancy
A pregnancy diagnosed by ultrasonographic examination of at least one fetus with a discernible heartbeat.
Time frame: Up to 30 days after transplantation
Miscarriage
The spontaneous loss of an intrauterine pregnancy.
Time frame: Up to 42 weeks after transplantation
Live birth
The complete expulsion or extraction from a woman of a product of fertilization, after 20 completed weeks of gestational age.
Time frame: Up to 42 weeks after transplantation
Gestational age at birth
The age of a fetus is calculated by the best obstetric estimate determined by assessments which may include early ultrasound.
Time frame: Up to 42 weeks after transplantation
Birthweight
Birth weight should be collected within 24 hours of birth and assessed using a calibrated electronic scale with ten-gram resolution.
Time frame: Up to 42 weeks after transplantation
Height of offspring 1 year old
Self-measurement
Time frame: Up to 1 year after delivery
Weight of offspring 1 year old
Self-measurement
Time frame: Up to 1 year after delivery
Embryo development rate
The proportion of cleaved embryos at the 4-cell stage on Day 2 (44 ± 1 h post-insemination) or at the 8-cell stage on Day 3 (68 ± 1 h post-insemination) per normally fertilized oocyte.
Time frame: Up to 3 days after insemination
1PN rate
The proportion of inseminated oocytes with one pronucleus on Day 1 (17 ± 1 h post-insemination).
Time frame: Up to 2 days after insemination
Blastocyst development rate
The proportion of blastocysts observed at 116 ± 2 h post-insemination as a function of the number of normally fertilized oocytes.
Time frame: Up to 7 days after insemination
Proportion of good blastocysts
The proportion of blastocysts with a grade of "good" or higher.
Time frame: Up to 7 days after insemination
Ectopic pregnancy
A pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization, or histopathology.
Time frame: Up to 30 days after transplantation
Gestational diabetes
By oral glucose tolerance test between 24 and 28 gestational weeks (fasting glucose ≥5.1 mmol/L, 1-h glucose ≥10.0 mmol/L, 2-h glucose ≥8.5 mmol/L; one abnormal result sufficient).
Time frame: Up to 30 weeks after transplantation
Gestational hypertension
Maternal systolic blood pressure ≥ 140 mmHg and (or) diastolic pressure ≥ 90 mmHg.
Time frame: Up to 42 weeks after transplantation
Major congenital anomaly
Structural, functional, and genetic anomalies, that occur during pregnancy, and identified antenatally, at birth, or later in life, and require surgical repair of a defect, or are visually evident, or are life-threatening, or cause death.
Time frame: Up to 42 weeks after transplantation
Neonatal mortality
Death of a live born baby within 28 days of birth.
Time frame: Up to 30 days after delivery
No study locations are listed for this record.
Plan to share: Yes — According to the policy of CITIC-Xiangya Reproductive and Genetic Hospital,research institutions could apply for data access by submitting a formal study protocol, subjected to approval by the hospital academic committee. Ethical review and research registration are mandatory for all studies.
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reproductive & Genetic Hospital of CITIC-Xiangya